Novartis India
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Novartis India is navigating a pivotal transition under new management, which is shifting from a passive legacy model to a proactive growth strategy. This transformation is crucial as the company aims to regain control over its flagship brands and expand its distribution in Tier 2 and Tier 3 markets. Despite the promising structural tailwinds from chronic therapies and an aging population, the company faces challenges from currency-induced cost inflation and increased competition from generics. Vista's financial outlook reflects a forecasted revenue contraction, yet an improvement in margins is anticipated as operational efficiencies are realized. The current valuation suggests that investors are pricing in long-term growth potential, despite the expected downside in revenue. The macroeconomic environment remains mixed, with inflationary pressures and currency dynamics posing risks. Over the next 12-24 months, key opportunities include leveraging the new management's strategic focus and expanding into underserved markets, while watchpoints include managing cost inflation and competitive pressures in the biosimilars space
Why We Like This Stock
- New management is implementing an aggressive growth strategy focused on brand control and market expansion
- Strong structural tailwinds in chronic therapies and an aging population support revenue stability
- Improving margins are expected as operational efficiencies are realized
Things To Watch Out For
- Revenue is forecasted to contract, reflecting challenges in the current market environment
- Currency-induced cost inflation and supply chain volatility may pressure profitability
- Increased competition from generics poses a significant threat to market share
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 335 | 356 | 354 | 386 | 423 |
| Profit Before Tax (Cr.) | 120 | 130 | 130 | 146 | 159 |
| PBT Margin | 35.9% | 36.5% | 36.7% | 38.0% | 37.7% |
| Net Profit (Cr.) | 83 | 101 | 95 | 108 | 117 |
| Earnings Per Share | 33.6 | 40.7 | 38.5 | 43.7 | 47.5 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Novartis India Limited is involved in the pharmaceutical business in India. The company offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neuroscience products under the Tegrital and Exelon brands. Novartis India Limited was incorporated in 1947 and is headquartered in Mumbai, India. As of July 29, 2026, Novartis India Limited operates as a subsidiary of Waverise Investments Limited.